Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 96 articles:
HTML format
Text format



Single Articles


    December 2017
  1. PRINTZ C
    Physicians discuss ramifications of studies pointing to breast cancer overdiagnosis: New research under way attempts to better define who should be screened and treated.
    Cancer. 2017;123:4525-4527.
    PubMed     Text format    


    November 2017
  2. MANNEVILLE F, Rotonda C, Conroy T, Bonnetain F, et al
    The impact of physical activity on fatigue and quality of life during and after adjuvant treatment for breast cancer.
    Cancer. 2017 Nov 8. doi: 10.1002/cncr.31108.
    PubMed     Text format     Abstract available


  3. OHRI N, Sittig MP, Tsai CJ, Hwang ES, et al
    Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis.
    Cancer. 2017 Nov 7. doi: 10.1002/cncr.31080.
    PubMed     Text format     Abstract available


  4. SENNERSTAM RB
    Reply to Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense?
    Cancer. 2017 Nov 6. doi: 10.1002/cncy.21924.
    PubMed     Text format    


  5. ALTUNDAG K
    Imaging modalities for the detection of distant metastases in breast cancer patients diagnosed in the 1970s and 1990s: Does it make any sense?
    Cancer. 2017 Nov 6. doi: 10.1002/cncy.21925.
    PubMed     Text format    


    October 2017
  6. WALLACE AS, Keene KS, Williams CP, Jackson BE, et al
    Radiation therapy utilization in Medicare beneficiaries with early-stage breast cancer.
    Cancer. 2017 Oct 20. doi: 10.1002/cncr.30989.
    PubMed     Text format     Abstract available


  7. GUTIERREZ BARRERA AM, Fouad TM, Song J, Webster R, et al
    BRCA mutations in women with inflammatory breast cancer.
    Cancer. 2017 Oct 17. doi: 10.1002/cncr.31069.
    PubMed     Text format     Abstract available


  8. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Text format     Abstract available


  9. DONALDSON AR, McCarthy C, Goraya S, Pederson HJ, et al
    Breast cancer risk associated with atypical hyperplasia and lobular carcinoma in situ initially diagnosed on core-needle biopsy.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31061.
    PubMed     Text format     Abstract available


  10. JAGSI R, Abrahamse PH, Lee KL, Wallner LP, et al
    Treatment decisions and employment of breast cancer patients: Results of a population-based survey.
    Cancer. 2017 Oct 9. doi: 10.1002/cncr.30959.
    PubMed     Text format     Abstract available


  11. ARLEO EK, Hendrick RE, Helvie MA, Sickles EA, et al
    Comparison of recommendations for screening mammography using CISNET models.
    Cancer. 2017;123:3673-3680.
    PubMed     Text format     Abstract available


    September 2017
  12. CHAOUL A, Milbury K, Spelman A, Basen-Engquist K, et al
    Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.30938.
    PubMed     Text format     Abstract available


  13. HARTMAN SJ, Nelson SH, Myers E, Natarajan L, et al
    Randomized controlled trial of increasing physical activity on objectively measured and self-reported cognitive functioning among breast cancer survivors: The memory & motion study.
    Cancer. 2017 Sep 19. doi: 10.1002/cncr.30987.
    PubMed     Text format     Abstract available



  14. More breast cancer patients could benefit from PARP inhibitors.
    Cancer. 2017;123:3433.
    PubMed     Text format    


  15. STURGEON KM, Hackley R, Fornash A, Dean LT, et al
    Strategic recruitment of an ethnically diverse cohort of overweight survivors of breast cancer with lymphedema.
    Cancer. 2017 Sep 7. doi: 10.1002/cncr.30935.
    PubMed     Text format     Abstract available


    August 2017
  16. SENNERSTAM RB, Franzen BSH, Wiksell HOT, Auer GU, et al
    Core-needle biopsy of breast cancer is associated with a higher rate of distant metastases 5 to 15 years after diagnosis than FNA biopsy.
    Cancer. 2017 Aug 24. doi: 10.1002/cncy.21909.
    PubMed     Text format     Abstract available


  17. BRAWLEY OW
    On assessing the effect of breast cancer screening schemes.
    Cancer. 2017 Aug 21. doi: 10.1002/cncr.30840.
    PubMed     Text format    


  18. PRINTZ C
    Scientists estimate number of U.S. women living with metastatic breast cancer: New data collection and interpretation activities will help advance treatment efforts.
    Cancer. 2017;123:2995-2996.
    PubMed     Text format    


  19. HAWLEY ST, Griffith KA, Hamilton AS, Ward KC, et al
    The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients.
    Cancer. 2017 Aug 15. doi: 10.1002/cncr.30924.
    PubMed     Text format     Abstract available


    July 2017
  20. POWIS M, Sutradhar R, Gonzalez A, Enright KA, et al
    Establishing achievable benchmarks for quality improvement in systemic therapy for early-stage breast cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30804.
    PubMed     Text format     Abstract available



  21. Perkins P, Cooksley CD and Cox JD. Breast cancer: Is ethnicity an independent prognostic factor for survival? Cancer. 1996;78:1241-1247.
    Cancer. 2017;123:2579.
    PubMed     Text format    


    June 2017
  22. SUBRAMANIAN S, Keating NL
    Delays in breast cancer diagnosis after a state policy limiting Medicaid enrollment.
    Cancer. 2017 Jun 26. doi: 10.1002/cncr.30769.
    PubMed     Text format    


  23. TARAZI WW, Bradley CJ, Bear HD, Harless DW, et al
    Impact of Medicaid disenrollment in Tennessee on breast cancer stage at diagnosis and treatment.
    Cancer. 2017 Jun 26. doi: 10.1002/cncr.30771.
    PubMed     Text format     Abstract available


  24. WALLNER LP, Li Y, McLeod MC, Hamilton AS, et al
    Decision-support networks of women newly diagnosed with breast cancer.
    Cancer. 2017 Jun 22. doi: 10.1002/cncr.30848.
    PubMed     Text format     Abstract available


  25. ABRAHAMS HJG, Gielissen MFM, Donders RRT, Goedendorp MM, et al
    The efficacy of Internet-based cognitive behavioral therapy for severely fatigued survivors of breast cancer compared with care as usual: A randomized controlled trial.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30815.
    PubMed     Text format     Abstract available


  26. AYUBI E, Safiri S
    Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry-methodological issues.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30852.
    PubMed     Text format    


  27. ZHANG FF, John EM
    Reply to Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry-methodological issues.
    Cancer. 2017 Jun 16. doi: 10.1002/cncr.30853.
    PubMed     Text format    


  28. PRINTZ C
    High-risk patients with breast cancer may not receive genetic testing.
    Cancer. 2017;123:1887.
    PubMed     Text format    


    May 2017
  29. KOROUKIAN SM, Bakaki PM, Htoo PT, Han X, et al
    The Breast and Cervical Cancer Early Detection Program, Medicaid, and breast cancer outcomes among Ohio's underserved women.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30720.
    PubMed     Text format     Abstract available


  30. BROWNE JP, Jeevan R, Gulliver-Clarke C, Pereira J, et al
    The association between complications and quality of life after mastectomy and breast reconstruction for breast cancer.
    Cancer. 2017 May 17. doi: 10.1002/cncr.30788.
    PubMed     Text format     Abstract available


  31. PRINTZ C
    Genomic sequencing of treatment-resistant metastatic breast cancer reveals key alterations.
    Cancer. 2017;123:904.
    PubMed     Text format    


  32. STOPECK AT
    Osteoclast inhibition in postmenopausal breast cancer: Is the evidence too strong to ignore?
    Cancer. 2017 May 2. doi: 10.1002/cncr.30678.
    PubMed     Text format    


  33. LIPTON A, Chapman JW, Leitzel K, Garg A, et al
    Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
    Cancer. 2017 May 2. doi: 10.1002/cncr.30682.
    PubMed     Text format     Abstract available


    April 2017
  34. HSU CD, Wang X, Habif DV Jr, Ma CX, et al
    Breast cancer stage variation and survival in association with insurance status and sociodemographic factors in US women 18 to 64 years old.
    Cancer. 2017 Apr 25. doi: 10.1002/cncr.30722.
    PubMed     Text format     Abstract available


  35. GUCALP A, Traina TA
    Androgen receptor-positive, triple-negative breast cancer.
    Cancer. 2017 Apr 12. doi: 10.1002/cncr.30683.
    PubMed     Text format    


  36. KATZ SJ, Wallner LP, Abrahamse PH, Janz NK, et al
    Treatment experiences of Latinas after diagnosis of breast cancer.
    Cancer. 2017 Apr 11. doi: 10.1002/cncr.30702.
    PubMed     Text format     Abstract available


  37. LIANG X, Margolis KL, Hendryx M, Reeves K, et al
    Effect of depression before breast cancer diagnosis on mortality among postmenopausal women.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30688.
    PubMed     Text format     Abstract available


  38. CASSIDY RJ, Liu Y, Kahn ST, Jegadeesh NK, et al
    The role of postmastectomy radiotherapy in women with pathologic T3N0M0 breast cancer.
    Cancer. 2017 Apr 7. doi: 10.1002/cncr.30675.
    PubMed     Text format     Abstract available


  39. PRINTZCANCER C
    Breast cancer mortality rates decline internationally, with some major exceptions.
    Cancer. 2017;123:1085.
    PubMed     Text format    


  40. PRINTZCANCER C
    Study to examine genetic factors behind increased risk of breast cancer in African Americans.
    Cancer. 2017;123:1083-1084.
    PubMed     Text format    


  41. KROENKE CH, Michael YL, Poole EM, Kwan ML, et al
    Postdiagnosis social networks and breast cancer mortality in the After Breast Cancer Pooling Project.
    Cancer. 2017;123:1228-1237.
    PubMed     Text format     Abstract available


    March 2017
  42. MAMTANI A, Patil S, Stempel MM, Morrow M, et al
    Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
    Cancer. 2017 Mar 23. doi: 10.1002/cncr.30658.
    PubMed     Text format     Abstract available


  43. HENRY NL, Braun TM, Breslin TM, Gorski DH, et al
    Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30674.
    PubMed     Text format     Abstract available


  44. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Chen WY, et al
    Body mass index, PAM50 subtype, recurrence and survival among patients with nonmetastatic breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30637.
    PubMed     Text format     Abstract available


  45. LIN HY, Bedrosian I, Babiera GV, Shaitelman SF, et al
    Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30660.
    PubMed     Text format     Abstract available


  46. LUCAS AR, Levine BJ, Avis NE
    Posttreatment trajectories of physical activity in breast cancer survivors.
    Cancer. 2017 Mar 8. doi: 10.1002/cncr.30641.
    PubMed     Text format     Abstract available


  47. FU J, Wu L, Jiang M, Li D, et al
    Real-world impact of non-breast cancer-specific death on overall survival in resectable breast cancer.
    Cancer. 2017 Mar 7. doi: 10.1002/cncr.30617.
    PubMed     Text format     Abstract available


  48. ZHANG FF, Haslam DE, Terry MB, Knight JA, et al
    Dietary isoflavone intake and all-cause mortality in breast cancer survivors: The Breast Cancer Family Registry.
    Cancer. 2017 Mar 6. doi: 10.1002/cncr.30615.
    PubMed     Text format     Abstract available


  49. KUCUK O
    Soy foods, isoflavones, and breast cancer.
    Cancer. 2017 Mar 6. doi: 10.1002/cncr.30614.
    PubMed     Text format    


  50. PRINTZ C
    Investigational drug combined with chemotherapy improves response in patients with BRCA-mutant breast cancer.
    Cancer. 2017;123:722-723.
    PubMed     Text format    


  51. KEAM B, Kim MK, Choi Y, Choi SJ, et al
    Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
    Cancer. 2017;123:841-848.
    PubMed     Text format     Abstract available


    February 2017
  52. WONG SM, Stout NK, Punglia RS, Prakash I, et al
    Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis.
    Cancer. 2017 Feb 21. doi: 10.1002/cncr.30644.
    PubMed     Text format     Abstract available


  53. BARCENAS CH, Raghavendra A, Sinha AK, Syed MP, et al
    Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30618.
    PubMed     Text format     Abstract available


  54. YEE MK, Sereika SM, Bender CM, Brufsky AM, et al
    Symptom incidence, distress, cancer-related distress, and adherence to chemotherapy among African American women with breast cancer.
    Cancer. 2017 Feb 15. doi: 10.1002/cncr.30575.
    PubMed     Text format     Abstract available


  55. PEPPERCORN J, Horick N, Houck K, Rabin J, et al
    Impact of the elimination of cost sharing for mammographic breast cancer screening among rural US women: A natural experiment.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30629.
    PubMed     Text format     Abstract available


  56. SADIM M, Xu Y, Selig K, Paulus J, et al
    Clinical and genetic predictors of weight gain in patients diagnosed with breast cancer.
    Cancer. 2017 Feb 14. doi: 10.1002/cncr.30628.
    PubMed     Text format     Abstract available


  57. DONALDSON AR, Shetty S, Wang Z, Rivera CL, et al
    Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30592.
    PubMed     Text format     Abstract available


  58. MILLER JA, Kotecha R, Ahluwalia MS, Mohammadi AM, et al
    Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies.
    Cancer. 2017 Feb 13. doi: 10.1002/cncr.30616.
    PubMed     Text format     Abstract available


  59. CRAGUN D, Weidner A, Lewis C, Bonner D, et al
    Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
    Cancer. 2017 Feb 9. doi: 10.1002/cncr.30621.
    PubMed     Text format     Abstract available


  60. SAAB J, Hoda RS, Narula N, Hoda SA, et al
    Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
    Cancer. 2017;125:128-137.
    PubMed     Text format     Abstract available


  61. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available


    January 2017
  62. RAGHAVENDRA A, Sinha AK, Le-Petross HT, Garg N, et al
    Mammographic breast density is associated with the development of contralateral breast cancer.
    Cancer. 2017 Jan 30. doi: 10.1002/cncr.30573.
    PubMed     Text format     Abstract available


  63. FRIESE CR, Harrison JM, Janz NK, Jagsi R, et al
    Treatment-associated toxicities reported by patients with early-stage invasive breast cancer.
    Cancer. 2017 Jan 24. doi: 10.1002/cncr.30547.
    PubMed     Text format     Abstract available


  64. BUYS SS, Sandbach JF, Gammon A, Patel G, et al
    A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Cancer. 2017 Jan 13. doi: 10.1002/cncr.30498.
    PubMed     Text format     Abstract available


  65. WATANABE T, Kuranami M, Inoue K, Masuda N, et al
    Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 stu
    Cancer. 2017 Jan 12. doi: 10.1002/cncr.30421.
    PubMed     Text format     Abstract available


  66. MORTIMER JE, Waliany S, Dieli-Conwright CM, Patel SK, et al
    Objective physical and mental markers of self-reported fatigue in women undergoing (neo)adjuvant chemotherapy for early-stage breast cancer.
    Cancer. 2017 Jan 6. doi: 10.1002/cncr.30426.
    PubMed     Text format     Abstract available


  67. LICHTENTHAL WG, Corner GW, Slivjak ET, Roberts KE, et al
    A pilot randomized controlled trial of cognitive bias modification to reduce fear of breast cancer recurrence.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30478.
    PubMed     Text format     Abstract available


    December 2016
  68. VAPIWALA N, Hwang WT, Kushner CJ, Schnall MD, et al
    No impact of breast magnetic resonance imaging on 15-year outcomes in patients with ductal carcinoma in situ or early-stage invasive breast cancer managed with breast conservation therapy.
    Cancer. 2016 Dec 16. doi: 10.1002/cncr.30479.
    PubMed     Text format     Abstract available


    November 2016
  69. SNEIGE N, Hess KR, Multani AS, Gong Y, et al
    Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
    Cancer. 2016 Nov 28. doi: 10.1002/cncr.30460.
    PubMed     Text format     Abstract available


  70. YEN TW, Pezzin LE, Li J, Sparapani R, et al
    Effect of hospital volume on processes of breast cancer care: A National Cancer Data Base study.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30413.
    PubMed     Text format     Abstract available


    October 2016
  71. FRIESE CR, Li Y, Bondarenko I, Hofer TP, et al
    Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer.
    Cancer. 2016 Oct 24. doi: 10.1002/cncr.30324.
    PubMed     Text format     Abstract available


  72. GOODWIN EA, Burhansstipanov L, Dignan M, Jones KL, et al
    The experience of treatment barriers and their influence on quality of life in American Indian/Alaska Native breast cancer survivors.
    Cancer. 2016 Oct 20. doi: 10.1002/cncr.30406.
    PubMed     Text format     Abstract available


  73. BRAND JS, Hedayati E, Bhoo-Pathy N, Bergh J, et al
    Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study.
    Cancer. 2016 Oct 11. doi: 10.1002/cncr.30364.
    PubMed     Text format     Abstract available


  74. GIORDANO SH, Niu J, Chavez-MacGregor M, Zhao H, et al
    Estimating regimen-specific costs of chemotherapy for breast cancer: Observational cohort study.
    Cancer. 2016 Oct 10. doi: 10.1002/cncr.30274.
    PubMed     Text format     Abstract available


    September 2016
  75. NYANTE SJ, Lee SS, Benefield TS, Hoots TN, et al
    The association between mammographic calcifications and breast cancer prognostic factors in a population-based registry cohort.
    Cancer. 2016 Sep 28. doi: 10.1002/cncr.30281.
    PubMed     Text format     Abstract available


  76. RAO R, Rivers A, Rahimi A, Wooldridge R, et al
    Genetic Ancestry using Mitochondrial DNA in patients with Triple-negative breast cancer (GAMiT study).
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30267.
    PubMed     Text format     Abstract available


    August 2016
  77. BRIER MJ, Chambless DL, Gross R, Chen J, et al
    Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
    Cancer. 2016 Aug 29. doi: 10.1002/cncr.30318.
    PubMed     Text format     Abstract available


    July 2016
  78. RUDDY KJ, Guo H, Baker EL, Goldstein MJ, et al
    Randomized phase 2 trial of a coordinated breast cancer follow-up care program.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30206.
    PubMed     Text format     Abstract available


  79. MANDELBLATT JS, Clapp JD, Luta G, Faul LA, et al
    Long-term trajectories of self-reported cognitive function in a cohort of older survivors of breast cancer: CALGB 369901 (Alliance).
    Cancer. 2016 Jul 22. doi: 10.1002/cncr.30208.
    PubMed     Text format     Abstract available


  80. FERRERO JM, Hardy-Bessard AC, Capitain O, Lortholary A, et al
    Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
    Cancer. 2016 Jul 14. doi: 10.1002/cncr.30170.
    PubMed     Text format     Abstract available


    June 2016
  81. DEGNIM AC, Dupont WD, Radisky DC, Vierkant RA, et al
    Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30153.
    PubMed     Text format     Abstract available


  82. DEGNIM AC, Visscher DW, Radisky DC, Frost MH, et al
    Breast cancer risk by the extent and type of atypical hyperplasia.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30151.
    PubMed     Text format    


  83. COLLINS LC, Schnitt SJ, Tamimi RM
    Reply to breast cancer risk by the extent and type of atypical hyperplasia.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30149.
    PubMed     Text format    


  84. OWUSU C, Margevicius S, Schluchter M, Koroukian SM, et al
    Vulnerable elders survey and socioeconomic status predict functional decline and death among older women with newly diagnosed nonmetastatic breast cancer.
    Cancer. 2016 Jun 27. doi: 10.1002/cncr.30046.
    PubMed     Text format     Abstract available


  85. GALIANO-CASTILLO N, Cantarero-Villanueva I, Fernandez-Lao C, Ariza-Garcia A, et al
    Telehealth system: A randomized controlled trial evaluating the impact of an internet-based exercise intervention on quality of life, pain, muscle strength, and fatigue in breast cancer survivors.
    Cancer. 2016 Jun 22. doi: 10.1002/cncr.30172.
    PubMed     Text format     Abstract available


  86. EATON BR, Jiang R, Torres MA, Kahn ST, et al
    Benefit of adjuvant radiotherapy after breast-conserving therapy among elderly women with T1-T2N0 estrogen receptor-negative breast cancer.
    Cancer. 2016 Jun 21. doi: 10.1002/cncr.30142.
    PubMed     Text format     Abstract available


  87. LEREBOURS F, Rivera S, Mouret-Reynier MA, Alran S, et al
    Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French t
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30143.
    PubMed     Text format     Abstract available


  88. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
    A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
    Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
    PubMed     Text format     Abstract available


  89. ROSS JS, Gay LM, Wang K, Ali SM, et al
    Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Cancer. 2016 Jun 10. doi: 10.1002/cncr.30102.
    PubMed     Text format     Abstract available


    May 2016
  90. DIELI-CONWRIGHT CM, Wong L, Waliany S, Bernstein L, et al
    An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy.
    Cancer. 2016 May 24. doi: 10.1002/cncr.30104.
    PubMed     Text format     Abstract available


  91. GIESE-DAVIS J, Bliss-Isberg C, Wittenberg L, White J, et al
    Peer-counseling for women newly diagnosed with breast cancer: A randomized community/research collaboration trial.
    Cancer. 2016 May 19. doi: 10.1002/cncr.30036.
    PubMed     Text format     Abstract available


  92. GUO X, Cai Q, Bao P, Wu J, et al
    Long-term soy consumption and tumor tissue MicroRNA and gene expression in triple-negative breast cancer.
    Cancer. 2016 May 16. doi: 10.1002/cncr.29981.
    PubMed     Text format     Abstract available


    April 2016
  93. PRINTZ C
    BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    Cancer. 2016;122:1149.
    PubMed     Text format    


    March 2016
  94. PRINTZ C
    Developments in precision medicine: Studies highlight new applications for cancer chemoprevention, treatment.
    Cancer. 2016;122:661-2.
    PubMed     Text format    


    February 2016
  95. HAAS JS, Hill DA, Wellman RD, Hubbard RA, et al
    Disparities in the use of screening magnetic resonance imaging of the breast in community practice by race, ethnicity, and socioeconomic status.
    Cancer. 2016;122:611-7.
    PubMed     Text format     Abstract available



  96. Prenatal exposure to maternal cancer with or without treatment does not impair child development.
    Cancer. 2016;122:338-9.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: